BioCentury
ARTICLE | Finance

Easy on the eyes

Kala series A funds to advance mucosal delivery technology in ophthalmics

March 4, 2013 8:00 AM UTC

Kala Pharmaceuticals Inc.'s $11.5 million series A round should allow the company to move its mucosal penetrating particle technology into the clinic for an ophthalmic indication.

New investor Crown Venture Fund led the round, in which existing investors Lux Capital, Polaris and Third Rock Ventures also participated. Kala raised $11.2 million in a seed round in 2012...